Wegovy Is Now Approved for Fatty Liver Disease. Read the Word 'Accelerated'.

What was approved

Wegovy's label now carries a third indication, alongside weight reduction and cardiovascular risk. It is approved for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis — MASH, formerly called NASH — with moderate to advanced liver fibrosis, stages F2 to F3, in adults¹.

That is a genuine regulatory finding for a liver disease that until very recently had almost no drug treatment at all.

Now read the next sentence of the label, because it changes what the first one means: this indication was granted under accelerated approval, based on improvement in MASH and fibrosis, and continued approval "may be contingent upon the verification and description of clinical benefit in a confirmatory trial"¹.

Accelerated approval means the drug was cleared on a marker that is expected to predict benefit — here, what a liver biopsy looks like — rather than on proof that people go on to live longer or avoid liver failure. That evidence is still being collected.

Why this is a women's page

Fatty liver gets discussed as a men's disease. For the reader of this site, the risk arrives with a life stage.

A 2023 systematic review and meta-analysis in Menopause pooled 12 studies comparing postmenopausal with premenopausal women. Menopause was associated with a pooled odds ratio of 2.37 for fatty liver disease (95% CI 1.99–2.82). In a sensitivity analysis restricted to the six studies that adjusted for age and metabolic factors, the association held at 2.19 (1.73–2.78)².

Roughly 2.4 times the odds, and it does not disappear when you control for getting older or for the metabolic changes that travel with menopause.

There is a second thing worth noticing about this particular approval, and it is rare enough to say out loud. The trial behind it was 57% female¹. For comparison, the cardiovascular outcome trials for this drug class — 11 trials, 82,140 participants — were 34.6% women⁴. On this question, for once, women were the majority of the evidence rather than a subgroup of it.

The numbers, with the placebo column

The trial is ESSENCE: 1,197 patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis, randomized 2:1 to weekly semaglutide 2.4 mg or placebo, running 240 weeks. What has been reported is a planned interim analysis at week 72 on the first 800 patients³. Everyone in both arms also received standard care for cardiometabolic conditions and lifestyle counseling¹.

The placebo column is the part to sit with. A third of people resolved their steatohepatitis without the drug, and more than a fifth improved their fibrosis. Both groups were being actively managed, and that is what active management plus a year and a half looks like on a biopsy.

The drug roughly doubles those rates. That is a real and useful effect. It is not the same claim as "62.9% of people got better because of semaglutide."

Two more findings from the same report: gastrointestinal adverse events were more common on semaglutide, and mean changes in bodily pain scores did not differ significantly between the groups³. If you were hoping this would make you feel different day to day, the trial did not find that.

What is still missing

The clinical endpoint. Biopsies improved. Whether that translates into fewer people progressing to cirrhosis, needing a transplant, or dying of liver disease is what the confirmatory work is for, and it is why the approval is provisional¹.

The rest of the 240 weeks. This is a week-72 readout of a trial designed to run more than four years³.

Representation beyond sex. Alongside that 57% female figure, 0.6% of participants were Black, and 27% were Asian¹. A trial can be unusually good on one axis and thin on another, and this one is.

Who funds it. The trial was funded by the manufacturer³. That is normal for phase 3 work and not a reason to dismiss it, but it belongs on the page.

What to do with this

If you have been told you have fatty liver, the useful question is no longer "is there anything for this" but "what stage am I." The approval is specific to F2–F3 fibrosis and to noncirrhotic disease. Below that stage and above it, this indication does not apply, and staging generally means imaging-based assessment or a biopsy rather than an ultrasound report that says "fatty liver."

If you are perimenopausal or past menopause and carrying metabolic risk, the Menopause meta-analysis is a reasonable prompt to ask whether your liver has ever been looked at². Fatty liver is usually silent, and it is not routinely screened.

Where this sits on the evidence scale

Strong, and provisional, at the same time. The trial is phase 3, randomized, double-blind, placebo-controlled, with histology from paired liver biopsies — the most rigorous endpoint available in this disease — and the effect sizes are large with confidence intervals well clear of zero³.

What has not been established is that any of it changes how long or how well people live, which is the question the confirmatory trial exists to answer and the reason the label says continued approval may depend on it¹. The menopause association is weaker evidence by design: 12 cross-sectional studies with substantial heterogeneity, which can show that the risk travels with menopause but cannot show that menopause causes it².